New approaches of chimeric antigen receptor (CAR)-immune cell-based therapy in gastric cancer; highlight CAR-T and CAR-NK DOI

Saade Abdalkareem Jasim,

Harikumar Pallathadka,

G. V. Sivaprasad

и другие.

Functional & Integrative Genomics, Год журнала: 2025, Номер 25(1)

Опубликована: Март 25, 2025

Язык: Английский

Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy DOI
Shaida Ouladan, Elias Orouji

Journal of Clinical Oncology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 13, 2025

Colorectal cancer (CRC) remains a major global health burden, being one of the most prevalent cancers with high mortality rates. Despite advances in conventional treatment modalities, patients metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful hematologic malignancies, presents promising avenue for treating solid tumors, including CRC. This review explores potential CAR-T therapy by analyzing clinical trials highlighting prominent CRC-specific targets. We discuss challenges such as immunosuppressive microenvironment, tumor heterogeneity, physical barriers that limit efficacy. Emerging strategies, logic-gated dual-targeting cells, offer practical solutions to overcome these hurdles. Furthermore, we explore combination immune checkpoint inhibitors enhance T-cell persistence infiltration. As field continues evolve, therapies hold significant revolutionizing landscape

Язык: Английский

Процитировано

0
Chimeric Cytokine Receptor TGF-β RⅡ/IL-21R Improves CAR-NK Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Gastric Cancer DOI Creative Commons

Yaojun Ren,

Min Xue,

Xinhui Hui

и другие.

Pharmacological Research, Год журнала: 2025, Номер 212, С. 107637 - 107637

Опубликована: Янв. 29, 2025

Gastric cancer remains a significant global health burden, characterized by regional variations in incidence and poor survival prospects advanced stages. Natural killer (NK) cells play crucial role the body's anti-cancer defense, chimeric antigen receptor (CAR)-NK cell therapy is gaining attention as cutting-edge promising treatment method. This study aims to tackle challenge of TGF-β-mediated tumor immune evasion within immunosuppressive microenvironment designing novel cytokine TRII/21R, which consists extracellular domains TGF-β II (TRII) transmembrane intracellular IL-21 (21R) can convert signal from (TME) into an NK activation through IL-21R-STAT3 pathway. We successfully constructed NKG2D-CAR-NK expressing TRII/21R demonstrated strong anti-tumor activity against both vitro vivo. The co-expression CAR-NK enhanced cytotoxicity, promoted proliferation capabilities, reduced expression exhaustion markers. In xenograft mouse model, TRII/21R-CAR-NK significantly inhibited growth improved rate tumor-bearing mice compared receiving control cells. Additionally, cells' infiltration, activation, persistence tumor, indicating robust response mediated JAK-STAT3 signaling underscores therapeutic potential TRII/21R-modified breakthrough strategy for combating cancer.

Язык: Английский

Процитировано

0
Nanoparticle-based Traditional Chinese Medicine for Immunotherapy in Gastrointestinal Tumors DOI Creative Commons

Linjia Peng,

Yan‐Feng Liang,

Qiuli Zhang

и другие.

Nano Biomedicine and Engineering, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
New approaches of chimeric antigen receptor (CAR)-immune cell-based therapy in gastric cancer; highlight CAR-T and CAR-NK DOI

Saade Abdalkareem Jasim,

Harikumar Pallathadka,

G. V. Sivaprasad

и другие.

Functional & Integrative Genomics, Год журнала: 2025, Номер 25(1)

Опубликована: Март 25, 2025

Язык: Английский

Процитировано

0